cefuroxime sodium: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
cefuroxime sodium: clinical details
Prescribing considerations
- Confirm that the infection and likely susceptibility fit cefuroxime's spectrum; obtain microbiology where appropriate.
- Use additional suitable antibacterial cover when anaerobic organisms are likely.
- Review renal function because systemic cefuroxime is primarily eliminated by the kidneys.
- Consider sodium content in patients requiring dietary sodium restriction.
- Apply antimicrobial-stewardship principles because cefuroxime is a UK Watch antibiotic.
- For intracameral use, follow product-specific aseptic reconstitution and administration instructions; do not compound systemic vials for ocular injection.
Contraindications and cautions
- Hypersensitivity to cefuroxime or cephalosporins.
- For systemic cefuroxime, a history of severe immediate hypersensitivity to another beta-lactam antibacterial.
- Do not restart systemic cefuroxime after cefuroxime-associated Stevens–Johnson syndrome, toxic epidermal necrolysis or DRESS.
Monitoring
- Clinical response and available culture or susceptibility results.
- Renal function, particularly with impairment, advanced age, aminoglycosides or potent loop diuretics.
- Neurological status if renal function is impaired or encephalopathy, myoclonus or seizures develop.
- Diarrhoea, Candida overgrowth, hypersensitivity and serious skin reactions.
- INR when used with oral anticoagulants.
- Blood counts and hepatic markers when clinically indicated; account for possible Coombs-test and glucose-assay interference.
- After intracameral use, postoperative vision, macula and corneal endothelium where clinically indicated.
Clinical pharmacology
A bactericidal, time-dependent second-generation cephalosporin that inhibits bacterial cell-wall synthesis through penicillin-binding proteins. Systemic cefuroxime is principally cleared by glomerular filtration and tubular secretion; intracameral administration produces negligible expected systemic exposure.
Formulation and product differences
- Systemic powder is prepared for intravenous or intramuscular administration and is not licensed or formulated for intracameral use.
- Ximaract is a dedicated single-use intracameral powder administered by an ophthalmic surgeon after cataract surgery.
- Reconstitution media, compatibility, inspection and disposal requirements are product-specific and must not be interchanged.
cefuroxime sodium preparations and strengths
Injection
Route: Parenteral
Strengths: 50 mg, 250 mg, 750 mg, 1.5 g
cefuroxime sodium interactions
Clinically relevant interactions mainly concern systemic cefuroxime; systemic interactions are unlikely with the intracameral eye product.
Probenecid
Delays cefuroxime elimination and increases systemic exposure, so concurrent use is not recommended.
Aminoglycoside antibiotics
May increase the risk of renal impairment; renal function may require closer monitoring.
Potent loop diuretics such as furosemide
May increase concern about renal impairment, particularly in older people or those with existing kidney disease.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.